At what point during first-line treatment with mono-immunotherapy for oligometastatic NSCLC is the ideal time to consider consolidative radiation/SBRT to the primary and oligometastatic sites?  

Much of this approach was designed with cytotoxic chemotherapy in mind -- wait "x" cycles, assess response, deliver radiation after chemotherapy. How do you view this concept for immunotherapy cycles? Would you stop immunotherapy during consolidative treatment?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice